Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug

Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Agent Who Need Emergent Temporary Catheter Insertion for Hemodialysis

Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The investigators designed a prospective study to evaluate the effect of desmopressin on platelet function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who were taking antiplatelet drugs.

Inclusion Criteria:

• adult uremic patients with one or more antiplatelet medication,
• prolonged collagen/epinephrine (CEPI) closure time,
• need for emergent hemodialysis and
• subsequent catheter insertion

Exclusion Criteria:

• acute coronary syndrome,
• hemophilia, and nephrogenic diabetes insipidus,
• allergy against desmopressin